NASDAQ:URGN
UroGen Pharma Ltd.
UroGen Pharma Ltd.'s revenue grew 21.4% in fiscal 2025 to $109.8M while operating margin fell to −113.7%. Free cash flow was −$162.7M, −148.2% of revenue.Summary generated from UroGen Pharma Ltd.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$109.8M
Revenue growth+21.4%
Revenue, 5-yr CAGR+56.2%
Gross margin88.7%
Operating margin−113.7%
Net margin−139.8%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$162.7M
FCF margin−148.2%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 48 | 64 | 83 | 90 | 110 |
| Operating income | −92 | −79 | −66 | −97 | −125 |
| Net income | −111 | −110 | −102 | −127 | −153 |
| Free cash flow | −86 | −88 | −77 | −97 | −163 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 4Insider transaction report
Sep 9, 2026 - 8-KOther events
Aug 20, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jun 23, 2026 - 8-KOther events
Jun 2, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026